Literature DB >> 32736769

Screening for occult cancer: where are we in 2020?

Samira Marín-Romero1, Luis Jara-Palomares2.   

Abstract

The relationship between venous thromboembolism (VTE) and cancer has become an area of intense debate due to the importance and the potential benefits of the identification of occult cancer following the diagnosis of unprovoked VTE. At present, extended screening is not recommended in patients with unprovoked VTE. However, if we were able to identify a group at greater risk of presenting cancer during follow-up, these patients would benefit from extended screening. The creation of a trans-organ screening model enables the unification of metrics of quality in the screening of cancer in different localizations. Likewise, it can incorporate cancer screening for other localizations or other specific situations of risk such as unprovoked VTE. This study summarizes the contribution of the Population-based Research Optimizing Screening through Personalized Regimens (PROSPR) initiative aimed at improving the cancer screening process. Likewise, we have carried out an updated review of unprovoked VTE and occult cancer. Finally, we discuss the studies currently ongoing aimed at identifying the population at greatest risk of presenting cancer during follow-up. The identification of this population at high risk could help to determine the following steps to undertake in order to implement screening in this population.
© 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Diagnostic screening programs; Early detection of cancer; Pulmonary embolism; Risk factors; Venous thromboembolism

Mesh:

Year:  2020        PMID: 32736769     DOI: 10.1016/S0049-3848(20)30390-X

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  1 in total

1.  Multi-territory stroke preceded by pulmonary embolism with asymptomatic coronavirus disease 2019: a case report.

Authors:  Jakob Van Herck; Hendrik Thoen; Christophe Delens; Joeri Voet
Journal:  Eur Heart J Case Rep       Date:  2021-11-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.